Read by QxMD icon Read


Maria Beran, Britta Okyere, Joshua Vova
Amantadine is commonly prescribed as a neurostimulant in patients with brain injuries. This is a case of a 14 year-old male with a history of brain tumor that developed corneal edema after initiation of amantadine, a rare but documented side effect of this medication. After discontinuation of amantadine, the corneal edema resolved within two months, but endothelial cells density remained low.
March 14, 2018: PM & R: the Journal of Injury, Function, and Rehabilitation
Daniëlle Bp Eekers, Lieke In 't Ven, Erik Roelofs, Alida Postma, Claire Alapetite, Neil G Burnet, Valentin Calugaru, Inge Compter, Ida E M Coremans, Morton Høyer, Maarten Lambrecht, Petra Witt Nyström, Alejandra Méndez Romero, Frank Paulsen, Ana Perpar, Dirk de Ruysscher, Laurette Renard, Beate Timmermann, Pavel Vitek, Damien C Weber, Hiske L van der Weide, Gillian A Whitfield, Ruud Wiggenraad, Esther G C Troost
PURPOSE: To create a digital, online atlas for organs at risk (OAR) delineation in neuro-oncology based on high-quality computed tomography (CT) and magnetic resonance (MR) imaging. METHODS: CT and 3 Tesla (3T) MR images (slice thickness 1 mm with intravenous contrast agent) were obtained from the same patient and subsequently fused. In addition, a 7T MR without intravenous contrast agent was obtained from a healthy volunteer. Based on discussion between experienced radiation oncologists, the clinically relevant organs at risk (OARs) to be included in the atlas for neuro-oncology were determined, excluding typical head and neck OARs previously published...
March 13, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Philipp Kickingereder, Ovidiu Cristian Andronesi
Magnetic resonance imaging plays a key role in diagnosis and treatment monitoring of brain tumors. Novel imaging techniques that specifically interrogate aspects of underlying tumor biology and biochemical pathways have great potential in neuro-oncology. This review focuses on the emerging role of 2-hydroxyglutarate-targeted magnetic resonance spectroscopy, as well as radiomics and radiogenomics in establishing diagnosis for isocitrate dehydrogenase mutant gliomas, and for monitoring treatment response and predicting prognosis of this group of brain tumor patients...
February 2018: Seminars in Neurology
Martha Nowosielski, Patrick Y Wen
The identification of more effective therapies for brain tumors has been limited in part by the lack of reliable criteria for determining response and progression. Since its introduction in 1990, the MacDonald criteria have been used in neuro-oncology clinical trials to determine response, but they fail to address issues such as pseudoprogression, pseudoresponse, and nonenhancing tumor progression that have arisen with more recent therapies. The Response Assessment in Neuro-Oncology (RANO) working group, a multidisciplinary international group consisting of neuro-oncologists, medical oncologists, neuroradiologists, neurosurgeons, radiation oncologists, and neuropsychologists, was formed to improve response assessment and clinical trial endpoints in neuro-oncology...
February 2018: Seminars in Neurology
Tracy Batchelor, Wolfgang Wick
No abstract text is available yet for this article.
February 2018: Seminars in Neurology
Victor A Levin
No abstract text is available yet for this article.
March 12, 2018: Neuro-oncology
Alessia Pellerino, Luca Bertero, Roberta Rudà, Riccardo Soffietti
Neoplastic meningitis (NM) is a devastating complication of solid tumors with poor outcome. Some randomized clinical trials have been conducted with heterogeneous inclusion criteria, diagnostic parameters, response evaluation and primary endpoints. Recently, the Leptomeningeal Assessment in Neuro-Oncology (LANO) Group and the European Society for Medical Oncology/European Association for Neuro-Oncology have proposed some recommendations in order to provide diagnostic criteria and response evaluation scores for NM...
2018: Therapeutic Advances in Neurological Disorders
Rohan Ramakrishna, Wei-Chun Hsu, Jialin Mao, Art Sedrakyan
OBJECTIVE: Surgeon volume has been previously shown to impact patient outcomes. However, data related to neuro-oncologic surgery is limited and does not include neurologic morbidities as an outcomes measure. In this study, we aimed to determine if 5-year surgeon cumulative and annual volumes predict early postoperative outcomes in patients following brain tumor surgery. METHODS: A population-based cohort of patients (n=10, 258) undergoing brain tumor resection between 2005 and 2014 were included for study utilizing the New York Statewide Planning and Research Cooperation System...
March 7, 2018: World Neurosurgery
Hari Nandu, Patrick Y Wen, Raymond Y Huang
Imaging plays several key roles in managing brain tumors, including diagnosis, prognosis, and treatment response assessment. Ongoing challenges remain as new therapies emerge and there are urgent needs to find accurate and clinically feasible methods to noninvasively evaluate brain tumors before and after treatment. This review aims to provide an overview of several advanced imaging modalities including magnetic resonance imaging and positron emission tomography (PET), including advances in new PET agents, and summarize several key areas of their applications, including improving the accuracy of diagnosis and addressing the challenging clinical problems such as evaluation of pseudoprogression and anti-angiogenic therapy, and rising challenges of imaging with immunotherapy...
2018: Therapeutic Advances in Neurological Disorders
Justin T Jordan, Amy E Sanders, Terri Armstrong, Tony Asher, Amy Bennett, Erin Dunbar, Nimish Mohile, P Leia Nghiemphu, Timothy R Smith, Douglas E Ney
No abstract text is available yet for this article.
March 2, 2018: Neuro-oncology
Linda Dirven, Terri S Armstrong, Jaishri O Blakeley, Paul D Brown, Robin Grant, Rakesh Jalali, Heather Leeper, Tito Mendoza, Lakshmi Nayak, Jaap C Reijneveld, Emilie Le Rhun, Tobias Walbert, Michael Weller, Patrick Y Wen, Martin J B Taphoorn
The Response Assessment in Neuro-Oncology-Patient-Reported Outcome (RANO-PRO) working group is an international multidisciplinary collaboration that provides guidance on the use of patient-reported outcome (PRO) measures in clinical trials and practice for adult patients with brain tumours. Findings from both PROs and traditional outcome measures, such as survival, and clinical or radiological response, are essential to inform the research community, policy makers, physicians, and patients in the treatment decision-making process...
March 2018: Lancet Oncology
Elena Vetlova, Denis A Golbin, Andrey V Golanov, Alexander A Potapov, Sergey M Banov, Natalia Antipina, Valery V Kostjuchenko, Dmitry Y Usachev, Artem Y Belyaev, Sergey Goryaynov
INTRODUCTION:  Preoperative stereotactic radiosurgery (pre-SRS) is a recent advancement in the strategy for brain metastasis (BM) management, and available data demonstrate the advantages of pre-SRS before postoperative radiation treatment, including lower rates of local toxicity, leptomeningeal progression, and a high percentage of local control. The authors presented the results of pre-SRS in patients with BM. MATERIALS AND METHODS: Nineteen patients with BM (11 female and eight male) have been treated at N...
December 26, 2017: Curēus
Silvia Schiavolin, Alberto Raggi, Chiara Scaratti, Matilde Leonardi, Alberto Cusin, Sergio Visintini, Francesco Acerbi, Marco Schiariti, Costanza Zattra, Morgan Broggi, Paolo Ferroli
BACKGROUND: This study aims to assess surgical outcome in brain tumor surgery using patient reported outcome measures (PROMs) and to compare their results with traditional clinical outcome measurements. METHOD: Neuro-oncological patients undergoing surgical removal for the lesion were enrolled; MOCA test, PROMs (EUROHIS-QoL, PGWB-S, WHODAS-12), and the clinical scale Karnofsky Performance Status (KPS) were administered to evaluate respectively cognitive status, quality of life, well-being, disability, and functional status before surgery and at 3-month follow-up...
March 3, 2018: Acta Neurochirurgica
Justin T Jordan, Amy E Sanders, Terri Armstrong, Tony Asher, Amy Bennett, Erin Dunbar, Nimish Mohile, P Leia Nghiemphu, Timothy R Smith, Douglas E Ney
No abstract text is available yet for this article.
March 2, 2018: Neurology
Carla Lucia Esposito, Silvia Nuzzo, Silvia Catuogno, Simona Romano, Filomena de Nigris, Vittorio de Franciscis
Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor in adults, and despite advances in neuro-oncology, the prognosis for patients remains dismal. The signal transducer and activator of transcription-3 (STAT3) has been reported as a key regulator of the highly aggressive mesenchymal GBM subtype, and its direct silencing (by RNAi oligonucleotides) has revealed a great potential as an anti-cancer therapy. However, clinical use of oligonucleotide-based therapies is dependent on safer ways for tissue-specific targeting and increased membrane penetration...
March 2, 2018: Molecular Therapy. Nucleic Acids
Xin Yu, Heyi Zheng, Matthew T V Chan, William K K Wu
Increasing studies have suggested that dysregulation of RNA-binding proteins (RBPs) contributes to cancer progression. Neuro-oncological ventral antigen 1 (NOVA1) is a novel RBP and plays an important role in tumour development. However, the expression and role of NOVA1 in melanoma remain unknown. In this study, we indicated that NOVA1 expression was up-regulated in melanoma samples and cell lines. Moreover, we demonstrated that knockdown of NOVA1 suppressed melanoma cell proliferation, migration and invasion in both A375 and A875 cell lines...
March 2, 2018: Journal of Cellular and Molecular Medicine
Mario Ganau, Marco Paris, Nikolaos Syrmos, Laura Ganau, Gianfranco K I Ligarotti, Ali Moghaddamjou, Lara Prisco, Rossano Ambu, Salvatore Chibbaro
The field of neuro-oncology is rapidly progressing and internalizing many of the recent discoveries coming from research conducted in basic science laboratories worldwide. This systematic review aims to summarize the impact of nanotechnology and biomedical engineering in defining clinically meaningful predictive biomarkers with a potential application in the management of patients with brain tumors. Data were collected through a review of the existing English literature performed on Scopus, MEDLINE, MEDLINE in Process, EMBASE, and/or Cochrane Central Register of Controlled Trials: all available basic science and clinical papers relevant to address the above-stated research question were included and analyzed in this study...
February 26, 2018: Medicines (Basel, Switzerland)
Surabhi Ranjan, Martha Quezado, Nancy Garren, Lisa Boris, Christine Siegel, Osorio Lopes Abath Neto, Brett J Theeler, Deric M Park, Edjah Nduom, Kareem A Zaghloul, Mark R Gilbert, Jing Wu
BACKGROUND: Immune checkpoint inhibitors (ICPIs) are being investigated in clinical trials for patients with glioblastoma. While these therapies hold great promise, management of the patients receiving such treatment can be complicated due to the challenges in recognizing immune-related adverse events caused by checkpoint inhibitor treatment. Brain imaging changes that are the consequence of an inflammatory response may be misinterpreted as disease progression leading to inappropriate premature cessation of treatment...
March 1, 2018: BMC Cancer
Andrea Pace, Tobias Walbert
No abstract text is available yet for this article.
February 19, 2018: Neuro-oncology
Matthias Seibl-Leven, Christian von Reeken, Roland Goldbrunner, Stefan Grau, Maximilian Ingolf Ruge, Norbert Galldiks, Veronika Dunkl, Martin Kocher, Raymond Voltz, Heidrun Golla
The implementation of self-reported outcome measurements into clinical routine was tested to help facilitate early access to palliative care (PC) for glioblastoma (GBM)-patients. Measures detail PC symptoms and concerns and caregiver burden. Between January 2014 and December 2016, a total of 337 GBM-patients were discussed during meetings of the neuro-oncology tumor board to examine further treatment options. Each patient, along with their caregivers, was requested to participate in self-assessment using the palliative outcome scale (POS) and the Zarit Burden Interview (ZBI)...
February 20, 2018: Journal of Neuro-oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"